Objective-To determine HIV-1 incidence and HIV-1 associated mortality in a prospective cohort study. To deterniine whether the cohort is suitable for studies aiming to determine the impact of interventions on HIV-1 incidence.
Introduction
Measuring the incidence of HIV infection is necessary to determine the rate of HIV transmission. In addition, when studies are planned to evaluate the efficacy of interventions to reduce HIV transmission, for instance through condom promotion, control of sexually transmitted diseases (STDs) or in future through immunisation against HIV-1, a reasonable estimate of the incidence of HIV infection is required for the determination of the size of the sample needed for the study.' However, there is limited information on the incidence of HIV-1 infection in Africa,2-'5 probably because incidence can only be measured in longitudinal studies which are difficult and costly to perform. '6 HIV-1 infection has been shown to contribute substantially to mortality in hospitals in Africa. '7-23 An obvious limitation of these studies is their selection bias, as in Africa many people die at home. Evidence from population-based studies is starting to emerge: in Rwanda and Uganda HIV-1 associated mortality was shown to be substantial.'52425 Quantification of HIV-1-associated mortality is important for assessment and prediction of the demographic and socio-economic impact of the epidemic. 2 28 A cohort study among urban factory workers in Mwanza, Tanzania, was started in October 1991 in order to determine the incidence of and risk factors for HIV-1 infection and other STDs, describe changes in sexual high risk behaviour following an intervention, and describe the natural history of HIV-1 infection. The prevalence of and risk factors for HIV-1 infection at intake of the cohort were found to be similar to those in the general urban population2930 and risk behaviour was found to be common: having multiple sexual partners in the past month was reported by 22% of male and 5% of female workers, while condoms were used by 3% only. 3' In this paper we describe the HIV-1 incidence and HIV-1 associated mortality in this cohort from October 1991 to September 1993.
Methods

Study population
The study population comprised workers at a large urban factory with a work force of 2038 workers (1706 men, 332 women). Enrolment started in October 1991 and continued throughout, both for new employees and those initially declining to participate. A study clinic was created at the factory to supplement an existing clinic, as the latter was too small to cope with additional activities. The study population was advised that the aim of the study was to determine the health status of the workers, with special interest in sexually transmitted diseases and HIV-1 infection and they were invited to present themselves for registration at the study clinic, on a voluntary basis. The study was in accordance with national guidelines on HIV testing and was approved by the ethical committee of the National Institute for Medical Research. The data presented here cover a study period of two years, from 1 October 1991 to 30 September 1993.
Data collection techniques
All respondents were interviewed, physically examined and underwent laboratory investigations at intake and at four-monthly intervals thereafter. Free medical treatment was provided to all study participants at intake, follow-up visits, and any time they presented in between. Where necessary, patients were referred to hospital for further investigation or treatment.
The interview took place in a private room for 30 Deaths among study participants were identified by a follow-up worker tracing nonattenders and through the welfare officer at the factory responsible for paying an allowance to the relatives of the deceased. The latter officer knew of all deaths identified, suggesting that his registration of deaths was comprehensive. The household of the deceased was visited by an assistant medical officer two to six months after death to interview the person who had taken care of the deceased before his or her death. If this per- The crude annual mortality rate was 4.9 per 100 person-years in those with and 0.3 in those without HIV-1 infection (table 2). The age and sex adjusted mortality ratio was 12-9 (95% CI 5.4-30 7). The age and sex adjusted population attributable risk was 0.5 per 100 person-years, and the population etiological fraction 62%.
Of the 14 HIV-1 infected people who died, nine met the criteria of the 1987 revised CDCtWHO AIDS case definition33: one had cryptococcal meningitis and eight HIV wasting syndrome. Two others had had weight loss and fever, but the evidence was inadequate to make or reject the diagnosis of AIDS. The remaining three without an AIDS diagnosis had pulmonary tuberculosis, diarrhoea and pyomyositis, respectively.
Discussion
In this cohort of urban factory workers with a prevalence of HIV-1 infection of 12%, the annual HIV-1 incidence rate was 1.2%. It is striking that at an HIV-1 prevalence of 12%, 62% of deaths in adults were attributable to HIV-1 infection, making it one of the most important public health problems in this urban, adult population. The incidence rate of HIV-1 infection in this study was similar to that in a cohort of urban health workers in Zaire,34 and rural population cohorts in Uganda,1415 but much lower than that of 4.7% in an urban population in a neighbouring Region in Tanzania,'1 which also had a much higher HIV-1 prevalence (of 24%) at the start of the study period. Urban women of childbearing age in Rwanda and Zambia also had higher incidence rates of 3-4%.6 As might be expected, the observed HIV-1 incidence was much lower than that of high risk groups in Africa such as spouses of HIV-1 infected people 7 10 prostitutes8 1213 and attenders of sexually transmitted disease clinics.5 Low HIV-1 incidence rates of approximately 2%35 and of 11 %36 were observed in prostitutes in low prevalence areas, though in the latter study a rapid increase in incidence rates over time was noted. 36 Mortality rates in those with and without HIV-1 infection were similar to those reported from Rwanda,25 while the population aetiological fraction in the present study of 62% was lower than that in Rwanda (90%), which is explained by the difference in HIV-1 prevalence (32% in Rwanda and 12% in the present study). In Uganda, mortality rates were approximately twice as high, both in those with and without HIV-1 infection,1524 resulting in a population aetiological fraction of 48% at an HIV-1 prevalence of 8%. '5 The population attributable risk is determined not only by the prevalence of the risk factor (HIV-1 infection) but also by the relative risk or mortality rate ratio. As might be expected, the mortality rate ratios in these three studies were not significantly different: they were reported to be 20-8 in Uganda and 12.9 in the present study, and can be estimated at approximately 28 in Rwanda. Confidence intervals are particularly wide in the present and the Rwanda study, because of the small numbers of deaths in non-HIV-1-infected people.
It seems likely that a sizeable proportion of deaths (at least 3/14 = 21%) occurred in HIV-1 infected people who had not yet developed AIDS, as was shown in Rwanda,9 Kenya,'9 and among intravenous drug users in the U.S.,'37-39 although because of data limitations a precise estimate of this proportion could not be made. Tuberculosis was diagnosed in 2 out of 14 deaths; an autopsy study in Ivory Coast40 suggests that a much larger proportion of deaths in the study population may have been attributable to tuberculosis than is evident from our data.
The study has a number of limitations. Although total enrolment was reasonable at 87% of those eligible, losses to follow-up were considerable at 19 per 100 person-years of follow-up. These losses to follow-up were largely due to two factors: many study participants did not like to submit blood samples repeatedly, and owing to economic difficulties the factory had to close down temporarily in the second year of the study, sending staff on unpaid leave. The first factor might be partly overcome by more intensive follow-up and education; the latter factor however, which affected in particular those in younger age groups, is much more serious, and may if repeated jeopardise the continuation of this cohort study.
The effect of these losses to follow-up may be an underestimate of the incidence of HIV-1 infection, if the incidence is highest in those less than 35 years old.'4 The effect on the mortality results is probably limited, as families of those sent on unpaid leave still qualified for receiving an allowance if a worker died.
For studies aiming to show that preventive interventions reduce the incidence of HIV-1 infection, a large sample size will be required to show an effect at a baseline incidence of 1.2%. For instance, if a vaccine against HIV-1 reduced the incidence of HIV-1 infection by 50% from 1.2 to 0.6 per 100 pyr, a sample size would be required in intervention and control group of approximately 5500 pyr each to have a 90% probability of showing that the vaccine is effective.
In conclusion, HIV-1 infection was a major public health problem, being the major cause of death in this adult population. At an HIV-1 incidence of 1-2 per 100 pyr, a large cohort size would be required to evaluate the impact of interventions on HIV-1 incidence. 
